Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | CD38 | P28907 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4632961 | 0.93 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL4592754 | 0.88 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL5902197 | 0.88 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL4593064 | 0.88 | CYP3A4 (0.46) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL5901943 | 0.87 | CYP3A4 (0.52) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL4593062 | 0.87 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL13983212 | 0.82 | CYP3A4 (0.45) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL5901801 | 0.82 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL5901175 | 0.80 | CYP1A2 (0.42) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL5901592 | 0.79 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP1A2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910313-A1 | 6-THIOAMIDE SUBSTITUTED BENZIMIDAZOLES | Nycomed GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2006100254-A1 | 6-THIOAMIDE SUBSTITUTED BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2006-09-28 | — | — | WO | disclosed |
| US-20060194969-A1 | 4-Substituted benzimidazoles and their uses as inhibitors of gastric secretion | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1575924-A1 | 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | ALTANA Pharma AG (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004054984-A1 | 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | ALTANA PHARMA AG (DE) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194969-A1 | 4-Substituted benzimidazoles and their uses as inhibitors of gastric secretion | GIPR, VIP, SI | CYP3A4 21/4885CYP2C9 226/4885CYP1A2 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.